Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib vs Lapatinib + Capecitabine in HER2+ Advanced Breast Cancer
NCT00777101Phase 2Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Feb 2009
- Primary completion
- Mar 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 31
01
Overview
A Phase 2 trial of neratinib in breast cancer, sponsored by Puma Biotechnology, Inc.. Started Feb 2009; status: completed.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00777101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777101.